C4 Therapeutics entered a collaboration with Roche to advance the degrader-antibody conjugate (DAC) modality and will work together on two programs to develop DACs against undisclosed targets. Financial terms and specific targets were not disclosed. The deal validates C4's degrader platform and is modestly positive for C4's pipeline outlook; absent financial or clinical details, market impact is likely limited.
C4 Therapeutics entered a collaboration with Roche to advance the degrader-antibody conjugate (DAC) modality and will work together on two programs to develop DACs against undisclosed targets. Financial terms and specific targets were not disclosed. The deal validates C4's degrader platform and is modestly positive for C4's pipeline outlook; absent financial or clinical details, market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
